evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract,articles/15/pmid,articles/15/title,articles/15/journal,articles/15/pubDate,articles/15/volume,articles/15/issue,articles/15/pages,articles/15/authors,articles/15/elocationId,articles/15/link,articles/15/reference,articles/15/abstract,articles/16/pmid,articles/16/title,articles/16/journal,articles/16/pubDate,articles/16/volume,articles/16/issue,articles/16/pages,articles/16/authors,articles/16/elocationId,articles/16/link,articles/16/reference,articles/16/abstract,articles/17/pmid,articles/17/title,articles/17/journal,articles/17/pubDate,articles/17/volume,articles/17/issue,articles/17/pages,articles/17/authors,articles/17/elocationId,articles/17/link,articles/17/reference,articles/17/abstract,articles/18/pmid,articles/18/title,articles/18/journal,articles/18/pubDate,articles/18/volume,articles/18/issue,articles/18/pages,articles/18/authors,articles/18/elocationId,articles/18/link,articles/18/reference,articles/18/abstract,articles/19/pmid,articles/19/title,articles/19/journal,articles/19/pubDate,articles/19/volume,articles/19/issue,articles/19/pages,articles/19/authors,articles/19/elocationId,articles/19/link,articles/19/reference,articles/19/abstract
18888,GENE_SUMMARY,,PDCD1 is a key mediator of immune self tolerance and several cancer entities highly express PDCD1 to evade anti-tumoral immune response. Anti-PD1 therapy has been successful in PD1 expressing cancer.,,2017-04-26,,5133,PDCD1,programmed cell death 1,False,ENST00000334409,NM_005018.2,hPD-l,SLEB2,CD279,PD1,PD-1,hSLE1,hPD-1,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18889,GENE_BACKGROUND,,"Programmed cell death protein 1 (PDCD1, PD1) is a surface receptor expressed on T-cells and pro-B cells and belongs to the immunoglobulin superfamily (PMID: 206368200, 12421930). It's ligands PD-L1/2 are important mediators of immune check point by preventing T-cell activation contributing to self-tolerance (PMID: 11209085, 11224527, 10485649). PD-L1 binding to PD1 leads to programmed cell death in antigen specific T-Cells and reduced apoptosis in regulatory T-cells which results in an overall decrease in immune response (PMID: 11857337, 16382236, 20208540). Several cancer entities highly express PD-L1 leading to immune evasion (PMID: 17195077, 12218188, 14871849, 15837746, 26359984). In the past years several drugs with inhibitory effects on PD1 have been developed and introduced into the clinic due to their therapeutic efficacy (PMID: 22658127, 26406148, 26412456, 26027431, 25891173, 25482239, 23724846). Tumors with defects in mismatch-repair seem more susceptible to PD-1 blockade (PMID: 26028255).",,2017-04-26,,5133,PDCD1,programmed cell death 1,False,ENST00000334409,NM_005018.2,hPD-l,SLEB2,CD279,PD1,PD-1,hSLE1,hPD-1,False,10485649,Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.,Immunity,0001-08-01,11,2,141-51,Nishimura H et al,,,0001-08-01,,26406148,Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.,The New England journal of medicine,2018-11-05T20:15:00,373,19,1803-13,Motzer RJ et al,doi: 10.1056/NEJMoa1510665,,0001-11-05,,17195077,Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.,"Cancer immunology, immunotherapy : CII",2018-05-01T20:07:00,56,5,739-45,Blank C et al,,,0001-05-01,,26027431,Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.,The New England journal of medicine,2018-07-02T20:15:00,373,True,23-34,Larkin J et al,doi: 10.1056/NEJMoa1504030,,0001-07-02,,11209085,Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.,"Science (New York, N.Y.)",2018-01-12T20:01:00,291,5502,319-22,Nishimura H et al,,,0001-01-12,,25891173,Pembrolizumab versus Ipilimumab in Advanced Melanoma.,The New England journal of medicine,2018-06-25T20:15:00,372,26,2521-32,Robert C et al,doi: 10.1056/NEJMoa1503093,,0001-06-25,,23724846,Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.,The New England journal of medicine,2018-07-11T20:13:00,369,2,134-44,Hamid O et al,doi: 10.1056/NEJMoa1305133,,0001-07-11,,26028255,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.,The New England journal of medicine,2018-06-25T20:15:00,372,26,2509-20,Le DT et al,doi: 10.1056/NEJMoa1500596,,0001-06-25,,20208540,Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.,Nature medicine,2018-04-01T20:10:00,16,4,452-9,Said EA et al,doi: 10.1038/nm.2106,,0001-04-01,,12421930,Expression of programmed death 1 ligands by murine T cells and APC.,"Journal of immunology (Baltimore, Md. : 1950)",2018-11-15T20:02:00,169,10,5538-45,Yamazaki T et al,,,2018-11-15T19:50:00,,12218188,Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.,Proceedings of the National Academy of Sciences of the United States of America,2018-09-17T20:02:00,99,19,12293-7,Iwai Y et al,,,0001-09-17,,16382236,Restoring function in exhausted CD8 T cells during chronic viral infection.,Nature,2018-02-09T20:06:00,439,7077,682-7,Barber DL et al,,,0001-02-09,,14871849,PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.,Cancer research,2018-02-01T20:04:00,64,3,1140-5,Blank C et al,,,0001-02-01,,26412456,Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.,The New England journal of medicine,2018-10-22T20:15:00,373,17,1627-39,Borghaei H et al,doi: 10.1056/NEJMoa1507643,,0001-10-22,,11857337,PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.,European journal of immunology,2018-03-01T20:02:00,32,3,634-43,Carter L et al,,,0001-03-01,,11224527,PD-L2 is a second ligand for PD-1 and inhibits T cell activation.,Nature immunology,2018-03-01T20:01:00,2,3,261-8,Latchman Y et al,,,0001-03-01,,15837746,Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-04-15T20:05:00,11,8,2947-53,Ohigashi Y et al,,,0001-04-15,,26359984,Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.,Cell,2018-09-10T20:15:00,162,6,1242-56,Kleffel S et al,doi: 10.1016/j.cell.2015.08.052,,0001-09-10,,22658127,"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.",The New England journal of medicine,2018-06-28T20:12:00,366,26,2443-54,Topalian SL et al,doi: 10.1056/NEJMoa1200690,,0001-06-28,,25482239,PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.,The New England journal of medicine,2018-01-22T20:15:00,372,4,311-9,Ansell SM et al,doi: 10.1056/NEJMoa1411087,,0001-01-22,
